Top Suppliers:I want be here
Related CAS#:
264233-05-8 834903-43-4
15341-31-8 852935-07-0
749872-43-3 314042-01-8
370586-05-3 313493-80-0
638156-11-3 2060006-09-7
2228422-43-1 2228340-62-1
2649062-59-7 2228340-64-3
2228209-26-3 2228980-87-6
2227911-94-4 2228094-31-1
2228422-51-1 2228340-71-2

264233-05-8

264233-05-8 structure
264233-05-8 structure
  • Name: CID 2745687
  • Chemical Name: Methyl 1-(2,4-difluorophenyl)-5-[(E)-{[(2-methyl-2-propanyl)carba mothioyl]hydrazono}methyl]-1H-pyrazole-4-carboxylate
  • CAS Number: 264233-05-8
  • Molecular Formula: C17H19F2N5O2S
  • Molecular Weight: 395.427
  • Catalog: Research Areas Cardiovascular Disease
  • Create Date: 2017-01-05 04:23:12
  • Modify Date: 2025-08-26 10:43:20
  • CID 2745687 acts as a specific, reversible and competitive GPR35 antagonist with a Ki of 12.8 nM[1].
Name Methyl 1-(2,4-difluorophenyl)-5-[(E)-{[(2-methyl-2-propanyl)carba mothioyl]hydrazono}methyl]-1H-pyrazole-4-carboxylate
Synonyms 1H-Pyrazole-4-carboxylic acid, 1-(2,4-difluorophenyl)-5-[(E)-[2-[[(1,1-dimethylethyl)amino]thioxomethyl]hydrazinylidene]methyl]-, methyl ester
ASTA 3746
Ciclonium bromide
Methyl 1-(2,4-difluorophenyl)-5-[(E)-{[(2-methyl-2-propanyl)carbamothioyl]hydrazono}methyl]-1H-pyrazole-4-carboxylate
Cicloniumbromid
Description CID 2745687 acts as a specific, reversible and competitive GPR35 antagonist with a Ki of 12.8 nM[1].
Related Catalog
In Vitro For ERK1/2 phosphorylation with 1 μM Pamoic acid as the agonist, the CID 2745687 (CID2745687) Ki is 18 nM[1]. CID 2745687 (CID-2745687) is a potent antagonist in β-arrestin-2 interaction assays only at human GPR35[2]. Using the BRET-based GPR35-β-arrestin-2 interaction assay and an EC80 concentration of Zaprinast (20 μM) as agonist, CID 2745687 behaved as a moderately potent, concentration-dependent antagonist at human GPR35 with pIC50=6.70±0.09[2]. CID 2745687 (pIC50=6.27±0.08) fully reverses the agonist action of Cromolyn disodium [2].
In Vivo CID 2745687 (CID2745687; 1 mg/kg; administrated orally every day for the last 4 weeks), a specific GPR35 antagonist, reverses Lodoxamide-mediated anti-fibrotic effects[3]. Animal Model: Six-week-old male C57BL/6 mice[3] Dosage: 1 mg/kg Administration: Oral administration, every day for 4 weeks Result: Inhibited Lodoxamide-mediated protective effects.
References

[1]. Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8.

[2]. Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343(3):683-95.

[3]. Mi-Jeong Kim, et al. Lodoxamide Attenuates Hepatic Fibrosis in Mice: Involvement of GPR35. Biomol Ther (Seoul). 2019 Jun 13;28(1):92-97.
Density 1.3±0.1 g/cm3
Boiling Point 493.6±55.0 °C at 760 mmHg
Molecular Formula C17H19F2N5O2S
Molecular Weight 395.427
Flash Point 252.3±31.5 °C
Exact Mass 395.122742
PSA 119.67000
LogP 3.05
Vapour Pressure 0.0±1.3 mmHg at 25°C
Index of Refraction 1.591
Hazard Codes Xi
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:264233-05-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 264233-05-8 | Chemsrc address: https://www.chemsrc.com/en/baike/1120207.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved